Covid19 Clinical Trial
Official title:
The Effect of Vitamin A Supplementation on Disease Improvement of Children With Moderate to Severe COVID-19.
Severe acute respiratory syndrome (SARS)-like coronavirus 2 (Sars-CoV-2) pandemia is considered to be the current major global health issue. With no specific treatment or vaccine known to be licensed, empowering the immune system to overcome the inflammatory status associated with the late stages of the disease, particularly by anti-inflammatory nutrients, is of great concern. Effective in reducing both the morbidity and mortality of respiratory infections, including measles, vitamin A and its derivatives are reported to enhance the immune system and/or antibody response to virus vaccinations in children, particularly those with vitamin insufficiency. Retinoids are, therefore, proposed as an adjunct therapy in the treatment of COVID-19. The study is aimed to investigate the effects of vitamin A supplementation on disease improvement in pediatric and adolescent patients with either moderate or severe COVID-19 disease.
| Status | Not yet recruiting |
| Enrollment | 60 |
| Est. completion date | December 19, 2021 |
| Est. primary completion date | November 21, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Month to 18 Years |
| Eligibility | Inclusion Criteria: - 1) aged between 1-month to 18-year old (boy or girl), 2) definitive or clinical diagnosis of severe acute respiratory syndrome (SARS)-like coronavirus 2 (SARS-COV-2) infection (by either a positive SARS-COV-2 polymerase chain reaction (PCR) test or a suggestive computed tomography (CT) scan, 3) no history or evidence of cancer or renal, hepatic, endocrine or viral disorders (including HIV/AIDS), 4) no history of supplementation either with vitamin A (VA) or with a multivitamin containing VA within the last 4 months, and 5) not participated in other clinical trials. Exclusion Criteria: - 1) mildly infected with SARS-COV-2 virus, and 2) pregnancy or lactation. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Shiraz University of Medical Sciences |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | 28-day mortality rate | COVID-19 mortality rate is defined as the number of deaths per 100 pediatric COVID-19 cases 28 days from the date of the intervention. | within 28 days from end of intervention | |
| Secondary | length of hospital stay | The length of hospital stay is defined as the difference between date of admission and date of discharge of the patient. | on the day of hospital discharge | |
| Secondary | length of pediatric intensive care unit (PICU) stay | The length of PICU stay is defined as the difference between date of PICU admission and date of PICU discharge of the patient. | on the day of PICU discharge | |
| Secondary | length of intubation | The length of intubation is defined as the difference between date of beginning and end of intubation | on the day of extubation | |
| Secondary | length of mechanical ventilation | The length of mechanical ventilation is defined as the difference between date of beginning and end of mechanical ventilation. | the weaning time of mechanical ventilation | |
| Secondary | multiple organ involvement | Multiple organ involvement is defined as one of either hematological, gastrointestinal, neurological, cardiovascular or hepatorenal complications. | on the day of the particular organ involvement | |
| Secondary | complete blood count (CBC)/diff | Complete blood count with differential | before and within 3 days from end of intervention | |
| Secondary | Prothrombin time (PT) | Prothrombin time | before and within 3 days from end of intervention | |
| Secondary | Partial thromboplastin time (PTT) | Partial thromboplastin time | before and within 3 days from end of intervention | |
| Secondary | International normalised ratio (INR) | International normalised ratio | before and within 3 days from end of intervention | |
| Secondary | fibrinogen | fibrinogen | before and within 3 days from end of intervention | |
| Secondary | troponin | troponin | before and within 3 days from end of intervention | |
| Secondary | Aspartate transaminase (AST) | Aspartate transaminase | before and within 3 days from end of intervention | |
| Secondary | Alanine transaminase (ALT) | Alanine transaminase | before and within 3 days from end of intervention | |
| Secondary | Blood urea nitrogen (BUN) | Blood urea nitrogen | before and within 3 days from end of intervention | |
| Secondary | Cr | Creatinine | before and within 3 days from end of intervention | |
| Secondary | Erythrocyte sedimentation rate (ESR) | Erythrocyte sedimentation rate | before and within 3 days from end of intervention | |
| Secondary | C-reactive protein (CRP) | C-reactive protein | before and within 3 days from end of intervention | |
| Secondary | Lactate dehydrogenase (LDH) | Lactate dehydrogenase | before and within 3 days from end of intervention | |
| Secondary | D-dimer | D-dimer | before and within 3 days from end of intervention | |
| Secondary | ferritin | ferritin | before and within 3 days from end of intervention | |
| Secondary | procalcitonin | procalcitonin | before and within 3 days from end of intervention | |
| Secondary | vitamin A concentration | vitamin A concentration | before and within 3 days from end of intervention |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |